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Abstract
Hereditary sensory neuropathy type I (HSN I) is a slowly progressive neurological disorder
characterised by prominent predominantly distal sensory loss, autonomic disturbances, autosomal
dominant inheritance, and juvenile or adulthood disease onset. The exact prevalence is unknown,
but is estimated as very low. Disease onset varies between the 2nd and 5th decade of life. The main
clinical feature of HSN I is the reduction of sensation sense mainly distributed to the distal parts of
the upper and lower limbs. Variable distal muscle weakness and wasting, and chronic skin ulcers
are characteristic. Autonomic features (usually sweating disturbances) are invariably observed.
Serious and common complications are spontaneous fractures, osteomyelitis and necrosis, as well
as neuropathic arthropathy which may even necessitate amputations. Some patients suffer from
severe pain attacks. Hypacusis or deafness, or cough and gastrooesophageal reflux have been
observed in rare cases. HSN I is a genetically heterogenous condition with three loci and mutations
in two genes (SPTLC1 and RAB7) identified so far. Diagnosis is based on the clinical observation and
is supported by a family history. Nerve conduction studies confirm a sensory and motor
neuropathy predominantly affecting the lower limbs. Radiological studies, including magnetic
resonance imaging, are useful when bone infections or necrosis are suspected. Definitive diagnosis
is based on the detection of mutations by direct sequencing of the SPTLC1 and RAB7 genes. Correct
clinical assessment and genetic confirmation of the diagnosis are important for appropriate genetic
counselling and prognosis. Differential diagnosis includes the other hereditary sensory and
autonomic neuropathies (HSAN), especially HSAN II, as well as diabetic foot syndrome, alcoholic
neuropathy, neuropathies caused by other neurotoxins/drugs, immune mediated neuropathy,
amyloidosis, spinal cord diseases, tabes dorsalis, lepra neuropathy, or decaying skin tumours like
amelanotic melanoma. Management of HSN I follows the guidelines given for diabetic foot care
(removal of pressure to the ulcer and eradication of infection, followed by the use of specific
protective footwear) and starts with early and accurate counselling of patients about risk factors
for developing foot ulcerations. The disorder is slowly progressive and does not influence life
expectancy but is often severely disabling after a long duration of the disease.
Disease name, synonyms, and historical terms 
(*)
Hereditary sensory neuropathy type I (HSN I)
Hereditary sensory and autonomic neuropathy type I
(HSAN I)
Charcot-Marie Tooth type 2B syndrome (HMSN 2B)
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Hereditary sensory radicular neuropathy*
Ulcero-mutilating neuropathy*
Thevenard syndrome*
Familial trophoneurosis*
Mal perforant du pied*
Familial syringomyelia*
Definition
Hereditary sensory neuropathy type I (HSN I) is a slowly
progressive neurological disorder characterised by promi-
nent predominantly distal sensory loss, autonomic distur-
bances, autosomal dominant inheritance, and juvenile or
adulthood disease onset.
Epidemiology
Hereditary sensory neuropathy type I (HSN I) constitutes
a clinically and genetically heterogenous group of disor-
ders of low prevalence. No detailed epidemiological data
are currently available. The disease frequency is still
reflected by reports of several affected families. Although
the impressive clinical features of HSN I are seen by neu-
rologists, general practitioners, orthopaedists and derma-
tologists, the condition might still be under-recognised.
This is particularly true for cases without family history
and those HSN I patients who do not exhibit the charac-
teristic clinical features.
Clinical description
Hereditary sensory neuropathies (HSN), also known as
hereditary sensory and autonomic neuropathies (HSAN),
belong to the large group of hereditary neuropathies. Typ-
ically, the HSNs predominantly affect peripheral sensory
and autonomic neurons but there is also variable motor
involvement [1]. The classification of the HSNs proposed
by Dyck et al was suggested before the detection of respon-
sible genes and was thus based on the age at onset, the
mode of inheritance and the predominant phenotype. It
comprises five main subtypes (HSN, HSAN types 1–5).
HSN (HSAN) type I (HSN I) is characterised by autosomal
dominant inheritance and juvenile or adulthood disease
onset. The congenital and early onset forms of HSN are
subcategorised as subtypes HSN II – V and are transmitted
by an autosomal recessive trait [1].
This review focuses on HSN type I. Molecular genetic stud-
ies in the past years have demonstrated genetic heteroge-
neity between the HSN I subtypes. The summary provided
in the next paragraph describes clinical and neurological
abnormalities in which the diagnosis HSN I should be
considered in a patient or a family.
A main and consistent feature of HSN I is the reduction of
sensation sense which is mainly distributed to the distal
parts of the upper and lower limbs (Table 1). Disease
onset varies between the 2nd and 5th decade of life. At the
beginning patients often notice distal sensory loss and/or
slow healing of wounds and/or chronic skin ulcers. The
latter changes appear due to permanent pressure, i.e. long
walks or when patients wear shoes that do not fit well.
Minimal wounds or blisters may then lead to deep foot
ulcerations. Other patients first recognise that they cannot
distinguish warm and cold stimuli, and that they are
insensitive to pain. When they get painless burns and
injuries they seek medical advice [1]. Neurological exam-
ination detects distal sensory disturbances, which may
affect all sensory qualities or selectively affect pain and
temperature sensation with preservation of vibration and
joint position sense. This dissociated sensory involvement
is typically seen in patiens with SPTLC1 mutations and
occurs in early stages of the disease [2]. The degree of
motor involvement is highly variable, even within fami-
lies, and ranges from absent to severe distal muscle weak-
ness and wasting of foot extensors leading to steppage
gait. In patients with marked involvement of the motor
nerves, the additional presence of prominent sensory
abnormalities and foot ulcerations are the only signs to
separate HSN I from hereditary motor and sensory neu-
ropathy (HMSN, i.e. Charcot-Marie-Tooth syndrome,
CMT) [3,4]. Foot deformity promotes ulcerations and
skin changes such as hyperkeratosis at pressure points,
which is also often prominent in HSN I. Serious and com-
mon complications are spontaneous fractures, osteomy-
elitis and necrosis, and neuropathic arthropathy which
may even necessitate amputations. Also autonomic fea-
tures are often observed and usually consist of sweating
disturbances. With progression of the disease, loss of sen-
sation and motor weakness may spread from distal parts
of the lower limbs to more proximal parts, but also the
hands may become similarly involved. In some reported
HSN I families, hypacusis or deafness, or cough and gas-
trooesophageal reflux have been observed. Some patients
experience positive symptoms of severe shooting, burning
and lancinating pain in the limbs or even in the trunk [1].
These symptoms are more frequently described in patients
with SPLTC1 mutations [2]. The disorder is slowly pro-
gressive, but is often severely disabling after a long dura-
tion of the disease [1,2,5].
Electrophysiological and nerve biopsy findings
In HSN I there is broad variability of electrophysiological
abnormalities within and between families. Primarily
axonal nerve damage of both motor and sensory nerves
has been shown. Sensory potentials are usually absent in
the lower limbs but are often recordable or even normal
in the upper limbs, particularly in females [1,6]. The study
of Whitaker et al in the family later shown to carry aOrphanet Journal of Rare Diseases 2008, 3:7 http://www.ojrd.com/content/3/1/7
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SPTLC1 mutation and the study by Dubourg et al also
show motor conduction slowing, possibly implying a
demyelinating process [7,8]. Neurophysiological studies
in CMT2B patients with a RAB7 mutation showed a mixed
motor and sensory neuropathy with axonal and some-
times also demyelinating nerve damage [2,9]. Sural nerve
biopsy findings were well studied in six English patients
with a SPTLC1 mutation. In severely affected nerves only
a very few myelinated fibres remained but electron micro-
scopy showed a reasonable number of unmyelinated
axons although the presence of stacks of flattened
Schwann cell processes suggested unmyelinated axon
loss. There was also some evidence for primary demyeli-
nation [6].
Aetiology
HSN I is a genetically heterogenous condition. In the past
two decades the introduction of genome-wide linkage
studies enabled genetic testing of several HSN families
and resulted in the elucidation of the molecular genetic
background of these diseases. Detailed family studies
clearly demonstrated clinical and genetic heterogeneity of
HSN I and three gene loci and two genes were subse-
quently identified [10]. Table 2 summarises the known
genes and gene loci and the phenotypic characteristics of
the HSN I subtypes. A clinician should always be aware
that the diagnosis of HSN I depends on patients having
severe sensory loss sufficient to cause painless injuries or
ulcerations. A comprehensive family history may also
often serve to a correct diagnosis.
A subdivision into HSN IA, HSN IB, HSN IC, and HSN ID
which is based on the different genetic background is pro-
posed here.
1. Hereditary sensory neuropathy type IA (HSN IA), also 
known as hereditary sensory and autonomic neuropathy 
(HSAN) type I
Historically, several families with juvenile and adulthood
HSN and suggestive autosomal dominant inheritance
have been reported. Most of the patients described in
these early reports exhibited the typical features of HSN
with pronounced distal sensory disturbances and acro-
mutilations, and sometimes also distal muscle involve-
ment. These families were diagnosed as HSN I in the clas-
sification proposed by Dyck [1]. In 1996, Nicholson et al
re-examined family members of a previously reported typ-
ical HSN I kindred [11]. Blood samples were taken from
affected and unaffected family members for genetic link-
age analysis. Subsequently, the disease gene in this HSN I
family was linked to chromosome 9q21–q22 and this
locus was confirmed in two further Australian families
[12]. In 2001, Dawkins et al showed that specific missense
mutations in the human gene serine palmitoyltransferase
long chain (SPTLC1) lead to HSN I. In this study, 11 out
of 24 families with HSN were screened and carried a path-
ogenic mutation in the SPTLC1 gene. This gene is ubiqui-
tously expressed and comprises 15 exons [13]. The most
common mutation was a single base substitution c.399T
> G in exon 5 of the SPTLC1 coding region resulting in a
single amino acid substitution of cysteine to tryptophan
(C133W) and was found in eight HSN I families of Aus-
tralian, English and Canadian origin. Two further less
common missense mutations in exons 5 and 6 (c.398G >
A and c.431T > A, i.e. C133Y and V144D) were identified
in an Austrian family and in a family of Australian/English
descendent [13]. Independently, Dawkins' findings were
confirmed by Bejaoui et al who reported the C133Y and
the C133W mutations in two further unrelated families
Table 1: Primary diagnostic criteria
Main features
Prominent/predominant distal sensory loss
Repeated foot ulcerations/acromutilations
Osteonecrosis
Additional criteria
Variable distal motor involvement
Foot deformity
Autonomic disturbances
Skin changes (hyperkeratosis, blisters, onychomycosis, etc.)
Autosomal dominant inheritance
Table 2: Classification of hereditary sensory neuropathies type I (HSN I)
Subtype Hallmark/additional features Locus Gene OMIM #
HSN IA Predominant loss of pain and temperature sensation, sometimes initial 
sign with long preservation of vibration sense, burning and lancinating 
pain, variable distal motor involvement, which may be severe.
9q22.1–q22.3 SPTLC1 162400
HSN IB Predominant sensory neuropathy with cough and gastro-oesophageal 
reflux, rarely foot ulcerations; normal distal muscle strength.
3p24–p22 unknown 608088
HSN IC (= CMT2B, HMSN IIB) Prominent distal motor involvement, often as initial sign of the disease, 
sensory loss of all qualities, acro-mutilating complications.
3q21 RAB7 600882
HSN ID Prominent sensory loss and mutilations in hands and feet, acropathy; 
variable motor involvement.
unknown unknown -Orphanet Journal of Rare Diseases 2008, 3:7 http://www.ojrd.com/content/3/1/7
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with typical HSN I [14]. Lateron, a novel missense muta-
tion c.1160G > C (G387A) in exon 13 was identified in
twin sisters from Belgium [15]. Known SPTLC1 mutations
were also confirmed in HSN I families from Czechia and
Portugal [16,17]. Nicholson et al pointed out that the sen-
sory-motor neuropathy phenotype caused by the c.399T >
G point mutation was the same as that reported by
Campell and Hoffmann and, possibly, the same as that
originally described by Hicks. Haplotype analysis in the
families reported by Dawkins demonstrated that three
Australian families of English extraction and three English
families had the same haplotype on chromosome 9 sug-
gesting a common founder as was the case in six of eight
families in an English study [6,18]. Subsequently, it was
suggested that SPTLC1 might be the causative gene in the
majority of HSN I patients. However, this was questioned
by a large study by Klein et al, in which only one SPTLC1
mutation was identified 25 HSN families tested [19]. All
mutations which have been identified as a cause of HSN I
are summarised in the Mutation Database of Inherited
Peripheral Neuropathies [20].
Serine palmitoyltransferase (SPT) is a pyridoxal-5'-phos-
phate dependent enzyme, which is suggested to be a key
enzyme for the regulation of sphingolipid levels in cells.
SPT in humans consists of two hetero subunits, SPTLC1
and SPTLC2 (or LCB1 and LCB2 in mammals), which are
both bound to the endoplasmic reticulum (ER) [21]. Reg-
ulation of sphingolipid synthesis at the SPT step prevents
a harmful accumulation of metabolic sphingolipid-inter-
mediates including sphingoid bases and ceramide,
whereas repression of other anabolic steps in the spingol-
ipid synthetic pathway may cause intermediates to accu-
mulate. It is still unclear why mutations in a protein
widely expressed in all tissues, trigger pathology that is
highly restricted to specific subsets of cells within a tissue
[22]. The C133W and V144D SPTLC1  mutations were
originally suggested to increase the serine palmitoyltrans-
ferase function with higher levels of glycosyl ceramide
compared to controls behaving as gain of function muta-
tions [13]. However, more recent studies showed that
both mutations reduce the normal serine palmitoyltrans-
ferase activity in various mammalian cell types, including
cultured lymphoblasts from HSN1 patients indicating
that  SPTLC1  mutations are dominant inactivating
[23,24]. The reason for the discrepancy of the two studies
is unknown [21]. Recently, Dedov et al carried out func-
tional studies in order to detect mechanisms leading to
the HSN I phenotype. Their tests using cells from HSN I
patients with the mutation T399G-(Cys133Trp) in the
SPTLC1 gene revealed a reduction of SPT activity in trans-
formed lymphocytes of 44%. Interestingly, this had no
effect on various spingolipid associated functions as de
novo biosynthesis, cellular sphingolipid content, cell pro-
liferation or death (apoptosis and necrosis). Other tests
showed similar results with no effects on viability of cells
after removal of extracellular sphingolipids, on permea-
bility to triton X-100 of primary lymphocytes, on viability
or in whole blood counts. Thus, the authors concluded a
sufficient actitivity of the non mutant allele for adequate
sphingolipid biosynthesis and cell viability. The authors
speculated that neurodegeneration in HSN1 is due to
rather subtle and long term effects like abnormal pro-
tein(s) similar to other neurodegenerations.
SPTLC2 is the second gene for the SPT protein, is located
on the chromosome 14q24.3–q31 and comprises 12
exons [21]. Screening of 12 index patients from families
with HSN excluded for mutations in the SPTLC1 gene did
not reveal any pathogenic mutations in the SPTLC2 gene.
The authors therefore concluded that SPTLC2 mutations
are not a common cause for hereditary sensory neuropa-
thy [25].
2. Hereditary sensory neuropathy type IB (HSN IB) (also 
known as hereditary sensory neuropathy with cough and 
gastrooesophageal reflux)
In 2002, Spring et al reported a family with an autosomal
dominant hereditary HSN. Patients had distal sensory loss
usually without foot ulcerations but adult onset of gastro-
oesophageal reflux and cough and no motor symptoms.
Cough could be triggered by noxious odours and could
lead to syncope. Nerve conduction studies, and sural and
skin biopsies revealed a sensory axonal neuropathy. Audi-
ometry showed sensorineural hearing loss in 4 out of 10
affected individuals [26]. The disease locus in this family
was linked to a 3.42 cM interval on chromosome 3p22–
p24 in 2003, and was also confirmed in a second family
with a similar phenotype [27]. Since then no further fam-
ilies with this rare form of HSN have been described. The
gene involved in this disease still remains to be identified.
3. Hereditary sensory neuropathy type IC (HSN IC), also 
known as Charcot-Marie-Tooth syndrome type 2B 
(CMT2B)
In 1995, Kwon et al carried out a clinical and genetical
study in a large American family with autosomal domi-
nant HMSN 2 (CMT2) [3]. In this family affected individ-
uals showed prominent distal muscle weakness and
wasting, sensory loss, and foot ulcerations which were fre-
quently complicated by toe and/or foot amputations. A
whole genome scan demonstrated linkage to chromo-
some 3q13–q22 [3]. Due to the prominent involvement
of motor fibres the disorder of this family was genetically
subcategorised among the hereditary motor and sensory
neuropathies (HMSN) and was termed HMSN2B
(CMT2B) [3,4]. With regard to the prominent ulcero-
mutilating complications this classification was ques-
tioned from the beginning because some authors argued
that the disease should have better been called HSN typeOrphanet Journal of Rare Diseases 2008, 3:7 http://www.ojrd.com/content/3/1/7
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1 [28]. The disease locus on chromosome 3q13–q22 was
confirmed in a small Scottish family and subsequenly in
an Austrian kindred and the critical interval was consider-
ably refined [9,29]. Finally in 2003, the causative gene of
CMT2B was identified and two missense mutations in the
small GTPase late endosomal protein RAB7 were detected
[30]. The Val162Met was found in exon 4 in the previ-
ously reported American and Scottish families as well as
in a small Austrian family. In the large Austrian family
described in 2001, the Leu129Phe in exon 3 was found to
be related to the disease. Later, this mutation was also
confirmed in further small Austrian families suggesting a
common founder, and in patients from Belgium and
Czechia [17,30]. A third missense mutation in exon 4 of
the RAB7 gene (Asn161Thr) was reported in 2004 in an
English family [31]. The mutation is located in a highly
conserved region adjacent to the reported Val162Met
mutation, and thus suggests that this region might be a
functionally important hotspot for RAB7 mutations [32].
RAB7 consists of 5 exons and belongs to the Rab family of
Ras-related GTP-ases. The Rab proteins are essential for
the regulation of intracellular membrane trafficking. They
may have a role in linking vesicles and target membranes
to the cytoskeleton [32,33]. The RAB7  gene has been
localised to late endosomes and has been shown to be
important in the late endocytic pathway. Although the
function of RAB7 has already been studied in detail, it
remains still unknown how mutations in the ubiquitously
expressed RAB7 gene cause a CMT2B neuropathy [30].
4. Hereditary sensory neuropathy type 1D (HSN ID)
Further genetic heterogeneity has been suggested in HSN
I [19,34,35]. Klein et al could not identify any mutations
in the RAB7 gene in the large series of HSN families and
in sporadic HSN patients of whom several affected indi-
viduals also had marked peroneal muscle wasting. Also,
linkage to the known HSN I loci has been excluded in a
few further families with autosmal dominant inheritance.
Thus, further genetic linkage studies in large families are
needed to identify new causative genes of HNS I [19].
Diagnostic methods
In a single patient, the clinical diagnosis of HSN I is based
on the observation of signs and symptoms described
above, and is supported by a family history suggesting
autosomal dominant inheritance. The diagnosis is sup-
ported by ancillary tests such as nerve conduction studies
which are needed to confirm a sensory and motor neurop-
athy predominantly affecting the lower limbs. In sporadic
cases acquired neuropathies have to be excluded (see dif-
ferential diagnosis) by use of several laboratory tests.
Radiological studies, including magnetic resonance imag-
ing, are useful when bone infections or necrosis are sus-
pected. With the discovery of several distinct HSN loci,
and ultimately the deciphering of the underlying gene
defects, the definitive diagnosis is now molecular and is
based on the detection of mutations by direct sequencing
of the SPTLC1 and RAB7 genes. Large families in which
mutations in SPTLC1 and RAB7 are excluded can be used
for genome wide linkage studies to detect a novel HSN I
locus or to confirm linkage to the third known HSN I
locus (i.e. the HSN IB locus). Such large HSN families will
be most helpful to identify further genes which are
involved in the pathogenesis of HSN I.
Differential diagnosis
HSN I must be distinguished from other forms of heredi-
tary sensory neuropathies (HSN types II-V). The pheno-
type of HSN II is often similar to that of HSN I. The main
differences are the autosomal recessive pattern of inherit-
ance of HSN II, an earlier disease onset, diffuse sensory
loss which is sometimes distributed to the whole body,
and less or no motor symptoms in HSN II. HSN II patients
also often exhibit early-onset of severe acro-mutilations in
the fingers. HSN III to HSN V can be easily distinguished
from HSN I because of congenital disease onset. Also,
these subtypes exhibit typical features such as the predom-
inant autonomic disturbances in HSN III or congenital
loss of pain and anhidrosis in HSN IV.
Particularly in sporadic patients with an HSN I phenotype
it is important to exclude acquired causes of ulcero-muti-
lating neuropathies. The major differential diagnoses are
the diabetic foot syndrome and alcoholic neuropathy.
Exclusion of other causes of neuropathies can usually be
done by laboratory and radiological studies, and requires
interdisciplinary discussion between neurologists, derma-
tologists, and orthopaedics. Table 3 summarises other dis-
eases which may mimick HSN I or are associated with
plantar foot ulcers.
Genetic counselling
As the disorder is inherited by an autosomal dominant
trait, previous family history is often reported. There is
thus a Mendelian risk of 50% for subsequent generations
independently from the sex of the affected individual and
Table 3: Differential diagnosis of hereditary sensory neuropathy 
type 1 and foot ulcerations
Hereditary sensory neuropathy type II
Diabetic foot syndrome
Alcoholic neuropathy
Neuropathies caused by other neurotoxins/drugs
Immune mediated neuropathy
Amyloidosis
Spinal cord diseases
Tabes dorsalis
Lepra neuropathy
Amelanotic melanoma and other skin tumours
ArtefactsOrphanet Journal of Rare Diseases 2008, 3:7 http://www.ojrd.com/content/3/1/7
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the child. Genetic counselling is an important tool for pre-
venting new cases if this is wished by at-risk family mem-
bers. Predictive testing of mutation carriers necessitates
accurate genetic counselling but is certainly useful for
young people to avoid serious complications of the dis-
ease.
Prenatal diagnosis
Molecular genetic diagnosis can be considered in families
where the disease causing mutation is known. However,
termination of pregnancy is not recommened in HSN1.
When a patient is male, artificial insemination with donor
sperm is another option that could be discussed with the
couple during genetic counselling.
Management
No gene-based therapies are available to date for any var-
iant of autosomal dominant HSN. Yet, accurate diagnosis
is important and is requested by patients and at-risk fam-
ily members. Ulcero-mutilating complications are the
most serious, prominent and leading diagnostic feature in
HSN I. The painless neuropathic foot ulcerations observed
in several subtypes of autosomal dominant HSN often
mimic foot ulcers caused by diabetic neuropathy and thus
resemble a "pseudodiabetic foot syndrome". Therefore, treat-
ment of foot ulcers and infections can follow the guide-
lines given for diabetic foot care which starts with early
and accurate counselling of patients about risk factors for
developing foot ulcerations. This of course includes
orthopaedic care and use of well fitting shoes without
pressure points. To date, treatment of foot complications
has reached an efficient level allowing treatment on an
outpatient basis. Early treatment of foot complications
often avoids hospitalisation and, in particular, complica-
tions like amputations. Principles of therapy are removal
of pressure to the ulcer, eradication of infection and spe-
cific protective footwear afterwards.
Prognosis
If patients with HSN I receive appropriate counselling and
treatment, the prognosis is good. Early treatment of foot
infections may avoid serious complications. Also the
complications are manageable, allowing an acceptable
quality of life. The disease is slowly progressive and does
not influence the life expectancy.
Unresolved questions
It is still unclear how mutations in the SPTLC1 and RAB7
genes lead to the phenotype of HSN I. For many families
and single HSN cases the genetic background still remains
unknown due to the genetic heterogeneity of the auto-
somal dominant HSN. There is still no causative treat-
ment of HSN. Pharmacological treatment or gene therapy
are needed but require a better understanding of the
molecular and functional mechanisms underlying the dif-
ferent genetic subtypes of HSN I.
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